Molclone Labs Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 2.50 M
as on 16-11-2024
- Company Age 11 Year, 13 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 18.50 Cr
as on 16-11-2024
- Satisfied Charges ₹ 5.90 Cr
as on 16-11-2024
- Revenue 34.80%
(FY 2023)
- Profit 67.44%
(FY 2023)
- Ebitda 13.38%
(FY 2023)
- Net Worth 44.94%
(FY 2023)
- Total Assets 53.93%
(FY 2023)
About Molclone Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹18.50 Cr. The company has closed loans amounting to ₹5.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kayalvizhi Thirumavalavan and Meikavalputhur Thirumavalavan serve as directors at the Company.
- CIN/LLPIN
U24100TN2013PTC094105
- Company No.
094105
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Molclone Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kayalvizhi Thirumavalavan  | Director | 10-Dec-2013 | Current |
| Meikavalputhur Thirumavalavan | Director | 10-Dec-2013 | Current |
Financial Performance of Molclone Labs.
Molclone Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.8% increase. The company also saw a substantial improvement in profitability, with a 67.44% increase in profit. The company's net worth Soared by an impressive increase of 44.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Molclone Labs?
In 2023, Molclone Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shri Ayyanar Phytochem Private LimitedInactive For E-Filing 9 months 4 daysKayalvizhi Thirumavalavan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Sep 2024 | ₹3.00 Cr | Open |
Others Creation Date: 27 Feb 2024 | ₹8.50 Cr | Open |
Others Creation Date: 27 Jul 2023 | ₹7.00 Cr | Open |
How Many Employees Work at Molclone Labs?
Unlock and access historical data on people associated with Molclone Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Molclone Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Molclone Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
